

Table 11.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1998 to 2007
Recipients with Heart Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	2,348	2,188	2,199	2,202	2,155	2,057	2,015	2,125	2,193	2,209
Tx with Antirejection Treatments	980	916	901	849	803	656	533	533	488	430
Antibodies										
Any in Category	21.3%	17.7%	16.3%	15.5%	17.4%	18.4%	15.6%	18.0%	19.3%	17.0%
Atgam/NRATG/NRATS	7.2%	6.3%	4.6%	3.9%	4.0%	4.6%	2.6%	2.4%	3.7%	5.1%
OKT3	15.0%	7.4%	5.1%	5.8%	6.8%	4.1%	3.2%	3.4%	3.7%	1.4%
Thymoglobulin	0.2%	2.0%	3.8%	4.9%	6.4%	7.5%	8.6%	9.4%	11.3%	9.3%
Zenapax	0.8%	2.5%	3.0%	2.5%	1.5%	2.0%	1.5%	3.6%	1.6%	2.6%
Simulect	0.1%	0.9%	2.0%	0.4%	0.4%	1.4%	0.6%	0.8%	0.4%	0.2%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.2%	0.2%	0.0%
Corticosteroids										
Any in Category	87.8%	91.3%	92.3%	92.7%	92.2%	92.5%	91.4%	90.8%	90.4%	89.5%
Steroids	87.8%	91.3%	92.3%	92.7%	92.2%	92.5%	91.4%	90.8%	90.4%	89.5%
Antimetabolites										
Any in Category	6.5%	4.6%	4.4%	2.0%	3.0%	3.5%	1.7%	2.3%	1.8%	2.3%
Cytosan	2.4%	2.1%	1.7%	0.5%	0.9%	1.7%	1.3%	1.3%	1.6%	2.1%
Methotrexate	4.3%	2.6%	2.8%	1.5%	2.1%	1.8%	0.4%	0.9%	0.2%	0.2%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.